Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings

Diana Huisin t Veld, Eric Balestre, Jozefien Buyze, Joris Menten, Antoine Jaquet, David A. Cooper, Francois Dabis, Constantin Yiannoutsos, Lameck Diero, Portia Mutevedzi, Matthew P. Fox, Eugene Messou, Christopher J. Hoffmann, Hans W. Prozesky, Matthias Egger, Jennifer J. Hemingway-Foday, Robert Colebunders

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world. Methods: Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively. Results: Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year. Conclusions: Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.

Original languageEnglish (US)
Pages (from-to)146-154
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume70
Issue number2
StatePublished - Oct 1 2015

Fingerprint

Body Weight Changes
HIV
Weights and Measures
Tenofovir
Stavudine
Weight Loss
Therapeutics
efavirenz
Body Weight
Databases
Central Asia
Central Africa
Nevirapine
Southern Africa
Eastern Africa
Western Africa
CD4 Lymphocyte Count
Linear Models
Acquired Immunodeficiency Syndrome
Logistic Models

Keywords

  • ART
  • Body weight determinants
  • HIV
  • Lowresource settings

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Veld, D. H. T., Balestre, E., Buyze, J., Menten, J., Jaquet, A., Cooper, D. A., ... Colebunders, R. (2015). Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings. Journal of Acquired Immune Deficiency Syndromes, 70(2), 146-154.

Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings. / Veld, Diana Huisin t; Balestre, Eric; Buyze, Jozefien; Menten, Joris; Jaquet, Antoine; Cooper, David A.; Dabis, Francois; Yiannoutsos, Constantin; Diero, Lameck; Mutevedzi, Portia; Fox, Matthew P.; Messou, Eugene; Hoffmann, Christopher J.; Prozesky, Hans W.; Egger, Matthias; Hemingway-Foday, Jennifer J.; Colebunders, Robert.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 70, No. 2, 01.10.2015, p. 146-154.

Research output: Contribution to journalArticle

Veld, DHT, Balestre, E, Buyze, J, Menten, J, Jaquet, A, Cooper, DA, Dabis, F, Yiannoutsos, C, Diero, L, Mutevedzi, P, Fox, MP, Messou, E, Hoffmann, CJ, Prozesky, HW, Egger, M, Hemingway-Foday, JJ & Colebunders, R 2015, 'Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings', Journal of Acquired Immune Deficiency Syndromes, vol. 70, no. 2, pp. 146-154.
Veld, Diana Huisin t ; Balestre, Eric ; Buyze, Jozefien ; Menten, Joris ; Jaquet, Antoine ; Cooper, David A. ; Dabis, Francois ; Yiannoutsos, Constantin ; Diero, Lameck ; Mutevedzi, Portia ; Fox, Matthew P. ; Messou, Eugene ; Hoffmann, Christopher J. ; Prozesky, Hans W. ; Egger, Matthias ; Hemingway-Foday, Jennifer J. ; Colebunders, Robert. / Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings. In: Journal of Acquired Immune Deficiency Syndromes. 2015 ; Vol. 70, No. 2. pp. 146-154.
@article{bcb33e439cf94231ac10cd27375135eb,
title = "Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings",
abstract = "Background: In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world. Methods: Data were extracted from the {"}International Epidemiologic Databases to Evaluate AIDS,{"} a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively. Results: Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year. Conclusions: Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.",
keywords = "ART, Body weight determinants, HIV, Lowresource settings",
author = "Veld, {Diana Huisin t} and Eric Balestre and Jozefien Buyze and Joris Menten and Antoine Jaquet and Cooper, {David A.} and Francois Dabis and Constantin Yiannoutsos and Lameck Diero and Portia Mutevedzi and Fox, {Matthew P.} and Eugene Messou and Hoffmann, {Christopher J.} and Prozesky, {Hans W.} and Matthias Egger and Hemingway-Foday, {Jennifer J.} and Robert Colebunders",
year = "2015",
month = "10",
day = "1",
language = "English (US)",
volume = "70",
pages = "146--154",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings

AU - Veld, Diana Huisin t

AU - Balestre, Eric

AU - Buyze, Jozefien

AU - Menten, Joris

AU - Jaquet, Antoine

AU - Cooper, David A.

AU - Dabis, Francois

AU - Yiannoutsos, Constantin

AU - Diero, Lameck

AU - Mutevedzi, Portia

AU - Fox, Matthew P.

AU - Messou, Eugene

AU - Hoffmann, Christopher J.

AU - Prozesky, Hans W.

AU - Egger, Matthias

AU - Hemingway-Foday, Jennifer J.

AU - Colebunders, Robert

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Background: In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world. Methods: Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively. Results: Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year. Conclusions: Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.

AB - Background: In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world. Methods: Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively. Results: Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year. Conclusions: Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.

KW - ART

KW - Body weight determinants

KW - HIV

KW - Lowresource settings

UR - http://www.scopus.com/inward/record.url?scp=84942021893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942021893&partnerID=8YFLogxK

M3 - Article

C2 - 26375465

AN - SCOPUS:84942021893

VL - 70

SP - 146

EP - 154

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 2

ER -